ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

11,957Medicare Part D Prescriptions Filled, Including Refills

Rank: 42 out of 198

$703K Total Retail Price of All Prescriptions

Rank: 29 out of 198

528 Patients Receiving at Least One Drug in Part D
96%Patients 65 Years and Older
18% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Nebraska
Lower avg

Schedule Two
Controlled Substances

3% of this provider’s 528 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

9% of this provider’s 528 patients filled at least one prescription for a schedule three drug, compared to an average of 10%.

Risky Drugs to Seniors

1% of this provider’s 11,602 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

23% of this provider’s prescriptions were for brand-name drugs, compared to an average of 25%.

Prescription Price

$59 was the average price of a prescription from this provider, compared to $53 among peers.

Prescriptions per Patient

23 is the average number of prescriptions (including refills) per patient, compared to an average of 22.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Nebraska
SIMVASTATIN 570 555 1 2
WARFARIN SODIUM 539 539 2 7
AMLODIPINE BESYLATE 477 477 3 4
LEVOTHYROXINE SODIUM 456 450 4 1
OMEPRAZOLE 413 397 5 3
FUROSEMIDE 268 263 6 5
BENAZEPRIL HCL 267 267 7 45
CARVEDILOL 262 262 8 24
LISINOPRIL 245 245 9 6
CITALOPRAM HBR 204 198 10 20
METOPROLOL SUCCINATE 201 199 11 11
POTASSIUM CHLORIDE 195 190 12 9
PRAVASTATIN SODIUM 190 186 13 19
METOPROLOL TARTRATE 188 188 14 10
ATENOLOL 173 173 15 17
GABAPENTIN 172 151 16 14
ATORVASTATIN CALCIUM 171 159 17 12
CRESTOR 170 161 18 26
METFORMIN HCL 158 158 19 13
HYDROCODONE-ACETAMINOPHEN 143 143 S3 20 8
ALENDRONATE SODIUM 131 131 21 21
LOSARTAN POTASSIUM 123 123 22 18
TAMSULOSIN HCL 116 116 23 27
ZOLPIDEM TARTRATE 106 106 24 22
SPIRONOLACTONE 100 97 25 37
RAMIPRIL 97 97 26 72
ALLOPURINOL 96 87 27 23
HYDROCHLOROTHIAZIDE 93 93 28 16
TRAMADOL HCL 89 89 29 15
POLYETHYLENE GLYCOL 3350 87 87 30 41
TORSEMIDE 86 84 31 75
PANTOPRAZOLE SODIUM 76 76 32 31
ESCITALOPRAM OXALATE 67 67 33 53
CLOPIDOGREL 66 66 34 42
TRIAMTERENE-HCTZ 66 60 34 32
NAMENDA 66 66 34 33
CARBIDOPA-LEVODOPA 64 64 37 71
DIOVAN 64 62 37 34
IPRATROPIUM BROMIDE 64 64 37 134
CYMBALTA 63 63 40 48
TERAZOSIN HCL 62 62 41 102
SPIRIVA 62 62 41 63
SPIRONOLACTONE-HCTZ 61 61 43 143
GLIMEPIRIDE 60 60 44 35
METHADONE HCL 57 47 S2 45 229
PREDNISONE 54 45 46 29
DONEPEZIL HCL 54 54 46 28
BISOPROLOL FUMARATE 51 51 48 87
SERTRALINE HCL 50 49 49 25
NEXIUM 50 37 49 40
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.